{
    "clinical_study": {
        "@rank": "147997", 
        "arm_group": {
            "arm_group_label": "Oral azacitidine", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To identify the maximum tolerated dose (MTD) of oral azacitidine in Japanese subjects with\n      myelodysplastic syndromes"
        }, 
        "brief_title": "Phase 1 Study of CC-486 in Japanese Subjects With Myelodysplastic Syndromes", 
        "completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Myelodysplastic Syndromes", 
        "condition_browse": {
            "mesh_term": [
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Twenty years of age to 80 years of age at the time of signing the informed consent\n             document 2. Understand and voluntarily sign an informed consent document prior to any\n             study related assessments and/or procedures being conducted 3. Able to adhere to the\n             study visit schedule and other protocol requirements 4. Have a documented diagnosis\n             of myelodysplastic syndromes according to World Health Organization 2008\n             classification.\n\n             5. Have at least one of the following:\n\n               -  Hemoglobin level \u2264 9.0 g/dL\n\n               -  Platelet count \u2264 50,000 /\u03bcL\n\n               -  Red blood cell transfusion-dependent as defined by:\n\n          -  Average red blood cell transfusion requirement of \u2265 4 units per 28 days confirmed for\n             a minimum of 84 days prior to starting study treatment. Hemoglobin levels within 7\n             days prior to administration of an red blood cell transfusion must be \u2264 9.0 g/dL in\n             order for the transfusion to be counted towards red blood cell transfusion-dependent\n             status. Red blood cell transfusions administered when hemoglobin levels were > 9.0\n             g/dL and/or red blood cell transfusions administered for elective surgery will not\n             qualify as a required transfusion for the purpose of providing evidence of red blood\n             cell transfusion-dependent status. Note that 4 units of red blood cell in Japan is\n             equivalent to 2 units of red blood cell outside of Japan.\n\n          -  No consecutive 42 days that are red blood cell-transfusion-free during the 84 days\n             prior to starting study treatment\n\n             \u2022 Platelet transfusion-dependent as defined by:\n\n          -  Have at least two separate platelet transfusion episodes during 56 days prior to\n             starting study treatment. Platelet transfusions administered for elective surgery\n             will not qualify as a required transfusion for the purpose of providing evidence of\n             platelet transfusion-dependent status.\n\n          -  No consecutive 28 days that are platelet-transfusion-free during the 56 days prior to\n             starting study treatment 6. ECOG performance status of 0, or 1 7. Females of\n             childbearing potential (FCBP: a sexually mature woman who: 1) has not undergone a\n             hysterectomy or bilateral oophorectomy or 2) has not been naturally postmenopausal\n             [ie, amenorrhea following cancer therapy does not rule out childbearing potential]\n             for at least 24 consecutive months [ie, has had menses at any time in the preceding\n             24 consecutive months]) must:\n\n               -  Agree to use at least two effective contraceptive methods (oral, injectable, or\n                  implantable hormonal contraceptive; tubal ligation; intra-uterine device;\n                  barrier contraceptive with spermicide; or vasectomized partner; injectable and\n                  implantable hormonal contraceptive have not been approved in Japan as of March\n                  2013) throughout the study, and for 3 months following the last dose of oral\n                  azacitidine; and\n\n               -  Have a negative serum or urine pregnancy test (sensitivity of at least 25\n                  mIU/mL) at screening; and\n\n               -  Have a negative serum or urine pregnancy test (investigator's discretion) within\n                  72 hours prior to starting study treatment (note that the screening serum\n                  pregnancy test can be used as the test prior to starting study treatment if it\n                  is performed within the 72-hour timeframe).\n\n                  8. Male subjects with a female partner of childbearing potential must agree to\n                  use at least 2 physician-approved contraceptive methods throughout the course of\n                  the study and should avoid fathering a child during the course of the study and\n                  for 3 months following the last dose of study drug.\n\n        Exclusion Criteria:\n\n          -  1. Hypoplastic myelodysplastic syndromes defined as bone marrow cellularity of < 20%\n             2. Chronic myelomonocytic leukemia, atypical chronic myeloid leukemia and\n             unclassifiable myeloproliferative disease. Subjects with white blood cell counts >\n             12,000/\u03bcL must be excluded.\n\n             3. Dry tap bone marrow aspirate due to myelofibrosis, and/or myelofibrosis\n             accompanied by splenomegaly 4. Prior treatment with azacitidine or other\n             hypomethylating agent 5. Prior allogeneic or autologous stem cell transplant 6.\n             History of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis),\n             celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other\n             gastrointestinal disorder or defect that would interfere with the absorption,\n             distribution, metabolism or excretion of the study drug and/or predispose the subject\n             to an increased risk of gastrointestinal toxicity 7. Thrombocytopenia secondary to\n             other possible causes, including medication(s), congenital disorder(s), immune\n             disorder(s) (eg, idiopathic thrombocytopenic purpura), or microvascular disorder(s)\n             (eg, disseminated intravascular coagulation, hemolytic uremic syndrome, thrombotic\n             thrombocytopenic purpura) 8. Use of any of the following within 28 days prior to\n             starting study treatment:\n\n               -  Cytotoxic, chemotherapeutic, investigational or targeted agents/therapies\n\n               -  Thrombopoiesis stimulating agents (eg, romiplostim, eltrombopag, interleukin-11)\n\n               -  Erythropoiesis stimulating agents or other red blood cell hematopoietic growth\n                  factors (eg, interleukin-3)\n\n               -  Hydroxyurea\n\n               -  Lenalidomide\n\n               -  Cyclosporine or antithymocyte globulin 9. Concurrent use of any of the\n                  following:\n\n               -  Corticosteroids, except for subjects on a stable or decreasing dose for at least\n                  1 week prior to starting study treatment for medical conditions other than\n                  myelodysplastic syndromes. Topical use of corticosteroids is permitted\n                  regardless of dose\n\n               -  Iron-chelating agents, except for subjects on a stable dose for at least 4 weeks\n                  prior to starting study treatment 10. Prior history of malignancies, other than\n                  myelodysplastic syndromes, unless the subject has been free of the disease for >\n                  3 years. Exceptions include the following:\n\n               -  Basal or squamous cell carcinoma of the skin\n\n               -  Carcinoma in situ of the cervix or breast\n\n               -  Incidental histological finding of prostate cancer (Tumor nodes metastasis stage\n                  of T1a N0M0 or T1b N0M0)\n\n               -  Early-stage gastric cancer suitable for endoscopic mucosal resection or\n                  endoscopic submucosal dissection 11. Significant active cardiac disease within\n                  the previous 6 months, including:\n\n               -  New York Heart Association class III-IV congestive heart failure\n\n               -  Unstable angina or angina requiring surgical or medical intervention\n\n               -  Myocardial infarction 12. Uncontrolled systemic fungal, bacterial, or viral\n                  infection (defined as ongoing signs/symptoms related to the infection without\n                  improvement despite appropriate antibiotics, antiviral therapy, and/or other\n                  treatment) 13. Known human immunodeficiency virus positivity (eg, subjects who\n                  are receiving antiretroviral therapy for human immunodeficiency virus disease)\n                  14. Hepatitis B surface antigen-positive, or hepatitis C virus\n                  antibody-positive. In case hepatitis B core antibody and/or hepatitis B surface\n                  antibody is positive even if hepatitis B surface antigen-negative, a hepatitis B\n                  virus deoxyribonucleic acid test should be performed and if positive the subject\n                  will be excluded 15. Any of the following laboratory abnormalities:\n\n               -  Absolute neutrophil count < 1,000/\u03bcL\n\n               -  Serum glutamic oxaloacetic transaminase/aspartate transaminase or serum glutamic\n                  pyruvate transaminase/alanine transaminase > 2.5 \u00d7 upper limit of normal\n\n               -  Serum bilirubin > 1.5 \u00d7 upper limit of normal. High levels are acceptable if\n                  these can be attributed to active red blood cell precursor destruction within\n                  the bone marrow (ie, ineffective erythropoiesis). Subjects are excluded if there\n                  is evidence of autoimmune hemolytic anemia manifested as a corrected\n                  reticulocyte count of > 2% with either a positive Coomb's test or over 50% of\n                  indirect bilirubin\n\n               -  Serum creatinine > 1.5 \u00d7 upper limit of normal\n\n               -  Serum bicarbonate (venous blood) < 22 mEq/L\n\n               -  Abnormal coagulation parameters (Prothrombin time-international normalized ratio\n                  > 1.5 or activated partial thromboplastin time > 40 seconds) 16. Known\n                  clinically significant anemia due to iron, vitamin B12, or folate deficiencies,\n                  or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding 17.\n                  History of cerebrovascular accident or transient cerebral ischemic attack within\n                  6 months prior to starting study treatment 18. Interstitial lung disease,\n                  pulmonary fibrosis, or other severe respiratory disease 19. Hepatic cirrhosis,\n                  or other moderate to severe hepatic disease 20. Known or suspected\n                  hypersensitivity to azacitidine or mannitol 21. Pregnant or lactating females\n                  22. Any significant medical condition, laboratory abnormality, or psychiatric\n                  illness that would prevent the subject from participating in the study 23. Any\n                  condition including the presence of laboratory abnormalities, which places the\n                  subject at unacceptable risk if he/she were to participate in the study 24. Any\n                  condition that confounds the ability to interpret data from the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01908387", 
            "org_study_id": "CC-486-MDS-001"
        }, 
        "intervention": {
            "arm_group_label": "Oral azacitidine", 
            "description": "100 mg to 300 mg oral azacitidine once daily for the first 21 days of the initial 28-day cycle", 
            "intervention_name": "Oral azacitidine", 
            "intervention_type": "Drug", 
            "other_name": "CC-486"
        }, 
        "intervention_browse": {
            "mesh_term": "Azacitidine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Oral azacitidine, CC-486, MDS, phase 1", 
        "lastchanged_date": "February 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kashiwa", 
                        "country": "Japan", 
                        "state": "Chiba", 
                        "zip": "277-8577"
                    }, 
                    "name": "National Cancer Center Hospital East"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "104-0045"
                    }, 
                    "name": "National Cancer Center Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "135-8550"
                    }, 
                    "name": "The Cancer Institute Hospital of JFCR"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Multicenter, Open-label, Dose-escalation Study of Oral Azacitidine (CC-486) in Japanese Subjects With Myelodysplastic Syndromes", 
        "overall_official": {
            "affiliation": "Celgene K.K.", 
            "last_name": "Toru Sasaki, Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of subjects experiencing dose limiting toxicity during the first 28-day cycle", 
            "measure": "Dose limiting toxicities", 
            "safety_issue": "Yes", 
            "time_frame": "For 28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01908387"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of participants with adverse events", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 4 years"
            }, 
            {
                "description": "Maximum observed concentration in plasma", 
                "measure": "Pharmacokinetics - Cmax", 
                "safety_issue": "No", 
                "time_frame": "On day 1 and day 8"
            }, 
            {
                "description": "Observed time to first maximum plasma concentration", 
                "measure": "Pharmacokinetics - tmax", 
                "safety_issue": "No", 
                "time_frame": "On day 1 and day 8"
            }, 
            {
                "description": "Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear trapezoidal rule", 
                "measure": "Pharmacokinetics - AUCt", 
                "safety_issue": "No", 
                "time_frame": "On day 1 and day 8"
            }, 
            {
                "description": "Area under the plasma concentration-time curve from time zero to infinity, calculated by the linear trapezoidal rule and extrapolated to infinity will be calculated according to the following equation:\nAUC\u221e = AUCt + (Ct/\u03bbz), where Ct is the last quantifiable concentration If the percentage of AUC extrapolated is \u2265 25%, AUC\u221e will not be reported.", 
                "measure": "Pharmacokinetics - AUC\u221e", 
                "safety_issue": "No", 
                "time_frame": "On day 1 and day 8"
            }, 
            {
                "description": "Percentage of AUC\u221e due to extrapolation from the time from the last quantifiable concentration to infinity, calculated as (AUC\u221e - AUCt) / AUC\u221e \u00d7100", 
                "measure": "Pharmacokinetics - AUCext%", 
                "safety_issue": "No", 
                "time_frame": "On day 1 and day 8"
            }, 
            {
                "description": "Terminal phase rate constant, determined by linear regression of the terminal points of the log-linear plasma concentration-time curve Visual assessment may be used to identify the terminal linear phase of the concentration versus time profile. A minimum of three data points will be used for calculation. \u03bbz will not be estimated if the terminal phase of the log-concentration versus time profile does not exhibit a linear decline phase, or if the regression coefficient < 0.8.", 
                "measure": "Pharmacokinetics - \u03bbz", 
                "safety_issue": "No", 
                "time_frame": "On day 1 and day 8"
            }, 
            {
                "description": "Terminal phase half-life, will be calculated according to the following equation:\nt1/2 = 0.693/\u03bbz", 
                "measure": "Pharmacokinetics - t1/2", 
                "safety_issue": "No", 
                "time_frame": "On day 1 and day 8"
            }, 
            {
                "description": "Apparent total clearance, calculated as Dose/AUC\u221e", 
                "measure": "Pharmacokinetics - CL/F", 
                "safety_issue": "No", 
                "time_frame": "On day 1 and day 8"
            }, 
            {
                "description": "Apparent volume of distribution will be calculated according to the equation:\nVz/F = (CL/F)/\u03bbz", 
                "measure": "Pharmacokinetics - Vz/F", 
                "safety_issue": "No", 
                "time_frame": "On day 1 and day 8"
            }, 
            {
                "description": "Cumulative amount excreted from time zero to time t (ng), calculated as the summation of the amounts (Aet, product of urine volume and urine concentration) excreted in subsequent collection intervals", 
                "measure": "Pharmacokinetics - Aet", 
                "safety_issue": "No", 
                "time_frame": "On day 1 and day 8"
            }, 
            {
                "description": "Cumulative fraction of dose excreted in the urine from time zero to time t (%), calculated as Ae t divided by dose", 
                "measure": "Pharmacokinetics - fet", 
                "safety_issue": "No", 
                "time_frame": "On day 1 and day 8"
            }, 
            {
                "description": "Renal clearance (mL/min), calculated as Aet divided by AUCt", 
                "measure": "Pharmacokinetics - CLr", 
                "safety_issue": "No", 
                "time_frame": "On day 1 and day 8"
            }, 
            {
                "description": "Number of participants with hematologic improvement using International Working Group (IWG 2006) criteria for Myelodysplastic Syndrome (MDS)", 
                "measure": "Hematologic response", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }, 
            {
                "description": "Number of participants with hematologic improvement using International Working Group (IWG 2006) criteria for Myelodysplastic Syndrome (MDS)", 
                "measure": "Hematologic improvement", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }, 
            {
                "description": "RBC transfusion independence is defined as the absence of any RBC transfusion during any consecutive 84 days during study treatment. For subjects who are RBC transfusion dependent at baseline, the percentage of subjects who achieved RBC transfusion independence on treatment will be provided.", 
                "measure": "Red blood cell (RBC) transfusion independence", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }, 
            {
                "description": "Platelet transfusion independence is defined as the absence of any platelet transfusion during any consecutive 56 days during study treatment. For subjects who are platelet transfusion dependent at baseline, the percentage of subjects who achieved platelet transfusion independence on treatment will be provided.", 
                "measure": "Platelet transfusion independence", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }
        ], 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014", 
        "why_stopped": "Protocol to be amended."
    }
}